361 related articles for article (PubMed ID: 8082082)
21. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
[TBL] [Abstract][Full Text] [Related]
22. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of soluble interleukin-2 receptor levels in the cerebrospinal fluid in patients with adult T-cell leukemia complicated with meningeal infiltration].
Tanaka K; Shiraishi K; Sakamoto A; Okubo Y; Fukuda Y; Fukahori S; Jojima H; Osabe S; Honda J; Natori H; Oizumi K
Gan To Kagaku Ryoho; 1996 Jun; 23(7):863-9. PubMed ID: 8678534
[TBL] [Abstract][Full Text] [Related]
25. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
26. [Eosinophil colony stimulating factor (Eo-CSF) activity and soluble interleukin-2 receptor (sIL-2R) in patients with reactive eosinophilia].
Watanabe K; Enokihara H; Saito K; Furusawa S
Arerugi; 1995 Nov; 44(11):1317-21. PubMed ID: 8857112
[TBL] [Abstract][Full Text] [Related]
27. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
28. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
29. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
[TBL] [Abstract][Full Text] [Related]
30. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
31. Cytokine profile during high-dose rhG-CSF therapy in severe congenital neutropenia.
Shitara T; Yugami S; Ijima H; Sotomatu M; Kuroume T
Am J Hematol; 1994 Jan; 45(1):58-62. PubMed ID: 7504401
[TBL] [Abstract][Full Text] [Related]
32. Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies.
Pavlidis NA; Manoussakis MN; Germanidis GS; Moutsopoulos HM
Med Pediatr Oncol; 1992; 20(1):26-31. PubMed ID: 1727208
[TBL] [Abstract][Full Text] [Related]
33. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
[TBL] [Abstract][Full Text] [Related]
34. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
Gorschlüter M; Bohlen H; Hasenclever D; Diehl V; Tesch H
Ann Oncol; 1995 May; 6(5):477-82. PubMed ID: 7545429
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
37. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
39. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
[TBL] [Abstract][Full Text] [Related]
40. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.
Stasi R; Conforti M; Del Poeta G; Simone MD; Coppetelli U; Tribalto M; Cantonetti M; Perrotti A; Venditti A; Papa G
Haematologica; 1992; 77(6):518-21. PubMed ID: 1289190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
